Limits...
Resuscitation Using Liposomal Vasopressin in an Animal Model of Uncontrolled Hemorrhagic Shock.

Lee MT, Wang HM, Ho JA, Fan NC, Yang YL, Lee CC, Chen SC - PLoS ONE (2015)

Bottom Line: The dynamic light scattering results confirmed that we had prepared a successful liposomal vasopressin complex.Comparing the serum vasopressin concentration of liposomal vasopressin and vasopressin treated animals by ELISA, we found that the concentration of vasopressin for the liposomal vasopressin treated group is higher at 60 minutes.We have synthesized a liposomal vasopressin complex that can prolong the serum concentration of vasopressin in a rat model of UHS.

View Article: PubMed Central - PubMed

Affiliation: Department of Emergency Medicine, National Taiwan University Hospital, Taipei, Taiwan.

ABSTRACT

Background: Current research suggests that administration of vasopressin to patients with uncontrolled hemorrhagic shock (UHS) can avoid the detrimental effects associated with aggressive fluid resuscitation. However, vasopressin has a short half-life of 10~35 minutes in in vivo use and precludes its use in the pre-hospital setting. To increase the half-life of vasopressin, we proposed to synthesize liposome-encapsulated vasopressin and test it in a rat model of UHS.

Methods: The film hydration method was used to prepare liposomal vasopressin consisting of: Dipalmitoylphosphatidylcholine, cholesterol, and dipalmitoyl phosphatidylethanolamine (20:20:1 mole ratio). 42 rats were subjected to UHS and randomly received 5 different treatments (vasopressin, liposomal vasopressin, lactate ringer (LR), liposome only and sham). Outcome of UHS were measured using 4 common prognostic tests: mean arterial pressure (MAP), serum lactate level, inflammatory profile and pulmonary edema.

Results: The dynamic light scattering results confirmed that we had prepared a successful liposomal vasopressin complex. Comparing the serum vasopressin concentration of liposomal vasopressin and vasopressin treated animals by ELISA, we found that the concentration of vasopressin for the liposomal vasopressin treated group is higher at 60 minutes. However, there was no significant difference between the MAP profile of rats treated with vasopressin and liposomal vasopressin in UHS. We also observed that animals treated with liposomal vasopressin performed indifferently to vasopressin treated rats in serum lactate level, inflammatory profile and edema profile. For most of our assays, the liposome only control behaves similarly to LR resuscitation in UHS rats.

Conclusion: We have synthesized a liposomal vasopressin complex that can prolong the serum concentration of vasopressin in a rat model of UHS. Although UHS rats treated with either liposomal vasopressin or vasopressin showed no statistical differences, it would be worthwhile to repeat the experiments with different liposomal compositions.

No MeSH data available.


Related in: MedlinePlus

Serum lactate levels for the five treatment groups over time.Vaso group refers to rats treated with vasopressin. Lipo vaso group refers to rats treated with liposomal vasopressin. LR group refers to rats treated with lactated ringer solution without any drug. Sham group refers to rats not undergoing any treatment. Lipo group refers to rats treated with liposome only.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4496076&req=5

pone.0130655.g003: Serum lactate levels for the five treatment groups over time.Vaso group refers to rats treated with vasopressin. Lipo vaso group refers to rats treated with liposomal vasopressin. LR group refers to rats treated with lactated ringer solution without any drug. Sham group refers to rats not undergoing any treatment. Lipo group refers to rats treated with liposome only.

Mentions: Serial measurements of mean (±SD) serum lactate level versus time plots in the five groups are shown in Fig 3. As expected, the serum lactate levels rose after inducing hemorrhagic shock in all the 4 groups of animals except the Sham group. The vasopressin treated group has a lower serum lactate profile than the liposomal vasopressin treated group (p <0.01). However, there is no significant difference between the serum lactate level in liposomal vasopressin, liposome only and LR treated rats.


Resuscitation Using Liposomal Vasopressin in an Animal Model of Uncontrolled Hemorrhagic Shock.

Lee MT, Wang HM, Ho JA, Fan NC, Yang YL, Lee CC, Chen SC - PLoS ONE (2015)

Serum lactate levels for the five treatment groups over time.Vaso group refers to rats treated with vasopressin. Lipo vaso group refers to rats treated with liposomal vasopressin. LR group refers to rats treated with lactated ringer solution without any drug. Sham group refers to rats not undergoing any treatment. Lipo group refers to rats treated with liposome only.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4496076&req=5

pone.0130655.g003: Serum lactate levels for the five treatment groups over time.Vaso group refers to rats treated with vasopressin. Lipo vaso group refers to rats treated with liposomal vasopressin. LR group refers to rats treated with lactated ringer solution without any drug. Sham group refers to rats not undergoing any treatment. Lipo group refers to rats treated with liposome only.
Mentions: Serial measurements of mean (±SD) serum lactate level versus time plots in the five groups are shown in Fig 3. As expected, the serum lactate levels rose after inducing hemorrhagic shock in all the 4 groups of animals except the Sham group. The vasopressin treated group has a lower serum lactate profile than the liposomal vasopressin treated group (p <0.01). However, there is no significant difference between the serum lactate level in liposomal vasopressin, liposome only and LR treated rats.

Bottom Line: The dynamic light scattering results confirmed that we had prepared a successful liposomal vasopressin complex.Comparing the serum vasopressin concentration of liposomal vasopressin and vasopressin treated animals by ELISA, we found that the concentration of vasopressin for the liposomal vasopressin treated group is higher at 60 minutes.We have synthesized a liposomal vasopressin complex that can prolong the serum concentration of vasopressin in a rat model of UHS.

View Article: PubMed Central - PubMed

Affiliation: Department of Emergency Medicine, National Taiwan University Hospital, Taipei, Taiwan.

ABSTRACT

Background: Current research suggests that administration of vasopressin to patients with uncontrolled hemorrhagic shock (UHS) can avoid the detrimental effects associated with aggressive fluid resuscitation. However, vasopressin has a short half-life of 10~35 minutes in in vivo use and precludes its use in the pre-hospital setting. To increase the half-life of vasopressin, we proposed to synthesize liposome-encapsulated vasopressin and test it in a rat model of UHS.

Methods: The film hydration method was used to prepare liposomal vasopressin consisting of: Dipalmitoylphosphatidylcholine, cholesterol, and dipalmitoyl phosphatidylethanolamine (20:20:1 mole ratio). 42 rats were subjected to UHS and randomly received 5 different treatments (vasopressin, liposomal vasopressin, lactate ringer (LR), liposome only and sham). Outcome of UHS were measured using 4 common prognostic tests: mean arterial pressure (MAP), serum lactate level, inflammatory profile and pulmonary edema.

Results: The dynamic light scattering results confirmed that we had prepared a successful liposomal vasopressin complex. Comparing the serum vasopressin concentration of liposomal vasopressin and vasopressin treated animals by ELISA, we found that the concentration of vasopressin for the liposomal vasopressin treated group is higher at 60 minutes. However, there was no significant difference between the MAP profile of rats treated with vasopressin and liposomal vasopressin in UHS. We also observed that animals treated with liposomal vasopressin performed indifferently to vasopressin treated rats in serum lactate level, inflammatory profile and edema profile. For most of our assays, the liposome only control behaves similarly to LR resuscitation in UHS rats.

Conclusion: We have synthesized a liposomal vasopressin complex that can prolong the serum concentration of vasopressin in a rat model of UHS. Although UHS rats treated with either liposomal vasopressin or vasopressin showed no statistical differences, it would be worthwhile to repeat the experiments with different liposomal compositions.

No MeSH data available.


Related in: MedlinePlus